News headlines about Keryx Biopharmaceuticals (NASDAQ:KERX) have trended somewhat positive on Tuesday, according to Accern. Accern scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Keryx Biopharmaceuticals earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.0914394992817 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the news headlines that may have impacted Accern’s scoring:
Several equities analysts have recently issued reports on the company. BidaskClub raised Keryx Biopharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, April 11th. Morgan Stanley reduced their target price on Keryx Biopharmaceuticals from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Thursday, February 8th. ValuEngine cut Keryx Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, February 22nd. Finally, Zacks Investment Research raised Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, April 11th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $7.19.
KERX stock traded up $0.17 during midday trading on Tuesday, hitting $4.72. The stock had a trading volume of 274,784 shares, compared to its average volume of 1,251,187. The stock has a market cap of $542.25, a price-to-earnings ratio of -5.38 and a beta of 2.60. Keryx Biopharmaceuticals has a 52-week low of $3.92 and a 52-week high of $8.38. The company has a quick ratio of 2.49, a current ratio of 3.12 and a debt-to-equity ratio of -8.87.
Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its quarterly earnings results on Wednesday, February 7th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by ($0.08). The firm had revenue of $18.70 million during the quarter, compared to analysts’ expectations of $17.53 million. Keryx Biopharmaceuticals had a negative return on equity of 10,954.62% and a negative net margin of 269.52%. Keryx Biopharmaceuticals’s revenue for the quarter was up 96.8% on a year-over-year basis. During the same period in the previous year, the company earned ($0.32) earnings per share. equities research analysts expect that Keryx Biopharmaceuticals will post -0.61 earnings per share for the current fiscal year.
In other Keryx Biopharmaceuticals news, CFO Scott A. Holmes sold 5,651 shares of the business’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $4.81, for a total value of $27,181.31. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, General Counsel Brian Adams sold 5,652 shares of the business’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $4.81, for a total value of $27,186.12. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 41,362 shares of company stock worth $199,640. 2.58% of the stock is owned by insiders.
WARNING: This story was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/04/17/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-keryx-biopharmaceuticals-kerx-stock-price.html.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis.
Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.